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Background/Aims:  Needle-track seeding is a rare but important complication of diagnostic and therapeutic ultrasound 
(US)-guided procedures in hepatocellular carcinoma (HCC). We examined the frequency of needle-track seeding after 
US-guided percutaneous ethanol injection (PEI), fine-needle aspiration biopsy (FNAB), and percutaneous transhepatic biliary 
drainage (PTBD) in order to determine the appropriate treatment for needle-track seeding and its clinical outcome. Methods: We 
analyzed the clinical characteristics and treatment outcomes in eight patients who experienced needle-track seeding from HCC 
after an US-guided procedure (FNAB, PEI, or PTBD) between January 1990 and July 2004. Results: Seven (0.14%) of 5,092 
patients who experienced needle-track seeding (2 after PEI, 4 after FNAB, and 1 after PTBD) during the study period and 1 other 
patient who experienced needle-track seeding recently were recruited for this study. Two of the eight patients underwent mass 
excision and the other six patients underwent en-bloc wide excision for the needle-track seeding. Tumors recurred in the needle- 
tracks in both patients who underwent mass excision but not in the six patients who underwent en-bloc wide excision. Mortality 
occurred in three patients who experienced the recurrence and progression of intrahepatic HCC. Conclusions: The incidence of 
needle-track seeding after US-guided procedures in HCC was 0.14%. En-bloc wide excision seems to be the optimal treatment 
for minimizing the probability of tumor recurrence due to needle-track seeding. (Korean J Hepatol 2011;17:106-112)
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INTRODUCTION
Hepatocellular carcinoma (HCC) is a common malignancy 
in Asia, where chronic hepatitis B and C infections are 
endemic. Furthermore, HCC constitutes more than 5% of all 
cancers and is the dominant cause of death in patients with 
compensated cirrhosis,
1,2 and its incidence is increasing 
globally, especially in the West.
3 
Ultrasound (US)-guided procedures are useful and versatile 
tools for the diagnosis and treatment of HCC, and have 
become increasingly popular since the late 1980s.
4 US- 
guided fine-needle aspiration biopsy (FNAB) is a widely 
accepted and minimally invasive technique for the cytological 
or histological diagnosis of HCC and is considered a safe 
and accurate method.
4,5 Percutaneous ethanol injection 
(PEI) is a safe and effective treatment modality in small 
HCC.
6 Percutaneous transhepatic biliary drainage (PTBD) is 
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jaundice due to bile duct invasion by HCC.
7 Although many 
complications have been reported to be associated with 
these procedures, the majority can be treated conservatively, 
with the notable exception of needle-track seeding.
8 However, 
needle-track seeding is rare after PEI or FNAB; reported 
incidences range from 0.65 to 2.2%
9,10 and from 1.5 to 
5.8%,
11 respectively. It has not been previously reported 
after PTBD (although tumor cell seeding has been reported 
along a catheter track in a patient with cholangiocarcinoma
12). 
Because of the rare incidence of needle-track seeding in 
HCC, the treatment options and prognosis of the needle-track 
seeding have not been properly addressed.
We performed this study to examine the frequency of 
needle-track seeding after US-guided procedures such as 
PEI, FNAB, and PTBD in HCC, and to determine the 
appropriate treatment for the needle-track seeding. In 
addition, we investigated the clinical courses in patients with 
the needle-track seeding from HCC.
PATIENTS AND METHODS
Patients
We retrospectively analyzed the computerized medical 
records of 5,092 patients who underwent PEI (1,549 
patients), FNAB (3,391 patients), or PTBD (152 patients) 
for HCC between January 1990 and July 2004 at Seoul 
National University Hospital. The study protocol was 
reviewed and approved by Institutional Review Board of 
Seoul National University Hospital.
Ultrasound-guided technique
Under US guidance (SSD-680 ultrasound scanner, Aloka, 
Tokyo, Japan, equipped with 3.5-MHz convex-array transducer), 
PEI and FNAB were performed using a 20-gauge needle 
with a closed conical tip, 3 terminal side holes (Gallini, 
Mirandola, Italy) and a biopsy device (Autovac Gun, 
Angiomed, Karlsruhe, Germany, equipped with 18 or 21- 
gauge needles) respectively. PTBD was performed with an 
8.5 Fr DM catheter (Cook, Winston-Salem, USA) under 
USG and fluoroscopic guidance. 
Data and image analysis
We retrospectively analyzed the medical records of patients 
who experienced needle-track seeding and collected the 
following data: age, gender, hepatitis viral marker, size of 
implanted nodule and primary HCC at the time of the first 
US-guided procedure, time interval from the US-guided 
procedure to the detection of implanted nodule, the extent of 
implanted nodule, the procedure involved, intrahepatic 
recurrence, method of nodule excision, degree of histologic 
differentiation of HCC, time interval from nodule excision 
to the last follow-up (in case of the recurrence of needle- 
track seeding, from nodule excision to detection of the 
recurrence), and survival. Association between these factors 
and recurrence after surgical excision were analyzed using 
Fisher’s exact test.
The locations of nodules were confirmed and their sizes 
were measured by physical examination and triple-phase 
helical computed tomography (CT). Patients underwent 
en-bloc wide excision or mass excision based on surgeon’s 
judgment. En-bloc wide excision was defined as the 
resection of implanted nodule with surrounding tissues such 
as, skin, subcutaneous tissue, muscles, and/or ribs. Mass 
excision was defined as removal of the implanted nodule 
only. The diagnosis of needle-track seeding was confirmed 
with the pathologic proof of metastatic HCC after excision.
RESULTS
Two (0.13%) of the 1,549 patients who underwent PEI, 
4 (0.12%) of the 3,391 who underwent FNAB, and one 
(0.66%) of the 152 patients who underwent PTBD for HCC 
experienced needle-track seeding during the study period. In 
addition, we also recruited one patient with needle-track 
seeding after PEI transferred from other hospital. Therefore, 
total 8 patients with needle-track seeding were enrolled 
(mean age, 48.5 years; range, 32-60 years). Table 1 
summarizes the baseline characteristics of the enrolled 
patients. Seven tumors occurred in the right hepatic lobe and 
one tumor in the left hepatic lobe. All of 8 patients had 
well-preserved liver function (Child-Pugh-Turcotte [CPT] 
score≤6) and no history of variceal bleeding, ascites, or 
encephalopathy. The size of tumors at the time of PEI, 
FNAB, or PTBD ranged from 2.5 to 8 cm (mean size, 4.0 
cm). Hepatitis B virus surface antigens were detected in 6 
patients, but no serologic marker for viral hepatitis was 
detected in the other two patients. Implanted nodules were 
detected 7 to 45 months (median; 10.5 months) after the 
procedures. The size of implanted nodules ranged from 1 to 108  The Korean Journal of Hepatology Vol. 17. No. 2, June 2011
Figure 1. Needle-track seeding (arrow) with skin involvement on 
a CT scan.
Figure 2. Needle-track seeding (arrow) without skin involvement 
on a CT scan.
Table 1. Baseline characteristics, treatments, and outcomes of eight patients with needle-track seeding from hepatocellular carcinoma
Case number
12345678
Age (yrs)/Gender 58/F 60/M 55/M 51/F 49/M 57/M 32/F 37/F
H B s A g +-++-+++
C P T  c l a s s AAAAAAAA
Size of primary HCC (cm) 3.8 3 3 6 2.9 3 2.5 8
Procedure PEI PEI PEI FNAB FNAB FNAB FNAB PTBD
Time interval
* ( m o n t h s ) 1 0 4 582 992 371 1
Size of implanted nodule (cm) 1 3.5 3.5 3 1 4 1 2.5
Skin involvement + - - + + - - +
Differentiation (Edmonson Grade) II II II III NA
† II II I
Method of excision WE WE WE WE ME
‡ WE ME
§ WE
Seeding recurrence - - - - + - + -
Hepatic recurrence - - - + - + - +
Time interval
¶ ( m o n t h s ) 1 0 8 7 26 47 5 8 3 11 52 3
Mortality - - - + NA
‡ +-
§ +
Survival (months) 110 73 67 75 NA
‡ 34 124
§ 24
*  Time interval from the US-guided procedure to the detection of implanted nodule.
†  Combined hepatocellular-cholangiocarcinoma. The differentiation could not be confirmed due to a lack of information.
‡  Clinical outcome in this patient could not be evaluated because of loss of follow-up.
§  This patients underwent repeated excision (en-bloc wide excision) for recurred tumor in needle track and did not experienced further 
recurrence of needle-track seeding.
¶  Time interval from nodule excision to the last follow-up (in case of the recurrence of needle-track seeding, from nodule excision 
to detection of the recurrence).
CPT, Child-Pugh-Turcotte; M, male; F, female; PEI, percutaneous ethanol injection;
FNAB, fine-needle aspiration biopsy; PTBD, percutaneous transhepatic biliary drainage;
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4 cm (mean; 2.4 cm, maximal diameter) at first excision. 
The skin was involved in four patients (Fig. 1, 2). 
Table 1 also summarizes the methods of surgical excision, 
the pathologic results, and the clinical outcomes in 8 patients 
with needle-track seeding. Six patients underwent en-bloc 
wide excision while other two patients underwent mass 
excision to manage needle-track seeding. Median follow-up 
after surgical excision was 43.8 monts (range 8-108 months). 
While no recurrence of needle-track seeding was observed 
in six patients who underwent en-bloc excision, other two 
patients who underwent mass excision experienced the 
recurrence of needle-track seeding after surgery. The 
implanted nodules at the time of first excision in these two 
patients who experienced the recurrence after surgery were 
smaller (1 cm) than those in other six patients who did not 
experienced the recurrence. One of these two patients had 
hepatitis B surface antigen and no skin involvement. This 
patient underwent en-bloc wide excision for the recurred 
implanted nodule and no intra or extra hepatic recurrence 
occurred during the study period. The other patient had no 
serologic markers for viral hepatitis and had skin involvement. 
The pathologic result of this patient revealed combined 
hepatocellular-cholangiocarcinoma. This patient did not 
receive any treatment for recurrence in our institution due 
to loss of follow-up. Because 8 of 5,092 patients had the 
pathologic results with combined hepatocellular-cholangio-
carcinoma during the study period, the frequency of needle- 
track seeding in this subgroup with combined hepatocellular- 
cholangiocarcinoma was 12.5% (one of eight patients).
Method of surgical excision, that is, en-bloc wide excision 
versus mass excision, was found to be significantly (P=0.036) 
associated with recurrence. On the other hand, Other factors 
such as age, gender, the presence of viral markers, the size of 
implanted nodule and primary HCC, the extent of implanted 
nodule, US-guided procedure used, time interval from the 
US-guided procedure to the detection of implanted nodule 
and intrahepatic recurrence were not found to be significantly 
associated with the recurrence of needle-track seeding. 
Degree of differentiation of the primary tumor could only be 
analyzed for seven of the eight patients, due to a lack of 
information on one, but was not found to be significantly 
associated with recurrence. 
During the study period, mortalities occurred in three 
patients (Table 1). These three patients received en-bloc wide 
excision for needle-track seeding and did not experience the 
recurrence after surgical resection. However, intrahepatic 
HCC recurred and progressed in these three patients during 
the study period. The patients died due to HCC progression 
and hepatic failure. Among two patients who experienced 
the recurrence of needle-track seeding after mass excision, 
one patient did not experienced further recurrence of needle- 
track seeding after repeated surgical treatment (en-bloc wide 
excision) and was alive by the end of the current study. 
Clinical outcome of the other patient who had combined 
hepatocellular-cholangiocarcinoma could not be evaluated 
due to follow-up loss.
DISCUSSION
In the current study, the incidence of needle-track seeding 
from HCC after a US-guided procedure (FNAB, PEI and 
PTBD) was 0.14% (7 of 5,092 patients) and the incidence of 
implanted nodule recurrence after surgical excision was 
25% (2 of 8 patients). Two patients who had undergone only 
mass excision instead of en-bloc wide excision experienced 
the recurrence of needle-track seeding after surgical 
excision. One of these underwent en-bloc wide excision for 
the recurred implanted nodule and experienced no further 
recurrence of needle-track seeding during the study period.
Biliary peritonitis, intra-and extrahepatic tumor seeding, 
and intrahepatic hematoma are the most serious complications 
of PEI, FNAB, and PTBD in HCC.
13-17 Complications after 
FNAB and PEI are rare, with reported incidences of 2.4% 
and 0.05-0.18% and mortality rates of 0.1% and 0.006- 
0.031%, respectively.
14,16,18-20 However, the overall complication 
rate after PTBD is higher with an incidence of 3.4-5%.
21 In 
the current study, two (0.13%) of the 1,549 patients who 
underwent PEI, four (0.12%) of the 3,391 patients who 
underwent FNAB, and one (0.66%) of the 152 patients who 
underwent PTBD for HCC experienced needle-track 
seeding. Silva et al in a systematic review and meta-analysis 
of eight observational studies found that the incidence of 
needle-track seeding after FNAB varied widely from 0-5.8%.
11 
As compared with previous reports, rates of needle-track 
seeding after PEI and FNAB were slightly lower in the 
current study. The number of patients in the current study 
was much larger than the previous observational studies, 
which would contribute to lower incidence in the current 
study due to the abundant experience.
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probably complex and several causes have been discussed.
22 
In animal models, Ryd et al found that FNAB can implant 
10
3-10
5 cells along a single needle-track.
23 Tumor size and 
degree of histologic differentiation, number of needle 
passes, the difference in the number of needle passes and 
the obtained specimens, the thickness of liver parenchyma 
along needle-tracks, and needle type have all been considered 
factors of needle-track seeding after FNAB in HCC.
24-29 
Kim et al reported that the number of needle passes 
seemed to affect the frequency of needle-track seeding and 
suggested that the life expectancies of patients influence the 
frequency of needle-track seeding more significantly than 
the size or degree of differentiation of HCC.
26 In addition, 
many cases of needle-track seeding after PEI have been 
reported.
9 Di Stasi et al reported that tumoral seeding after 
PEI occurs for deeply located and small HCCs, but found no 
relation between seeding risk and HCC cytology.
9
No report has been issued on the recurrence of needle- 
track seeding and the factors associated to the recurrence in 
HCC. In the current study, the recurrence rate of needle- 
track seeding was 25% among our eight patients at a median 
follow-up of 43.8 months. And we found that only the 
method of excision for implanted nodules was significantly 
associated with recurrence while other factors were not; no 
patients who had undergone en-bloc wide excision experienced 
the recurrence of needle-track seeding. Furthermore, our 
findings show that PTBD, like PEI and FNAB, can cause 
needle-track seeding.
Nevertheless, despite the risks of needle-track seeding, 
PEI, FNAB and PTBD are useful tools for diagnosing and 
treating HCC, because it appears that needle-track seeding 
does not exacerbate the disease course. Several studies have 
reported that the prognosis of needle-track seeding from 
HCC after PEI or FNAB is favorable and similar to that of 
patients who do not develop seeding, although these 
studies concerned clinical follow-ups on small numbers of 
patients.
9,20,30 Despite the fact that only eight patients were 
included in the current study, it is the largest study conducted 
to date on the prognosis of needle-track seeding. In the 
current study, needle-track seeding, when it was treated by 
en-bloc side excision, did not seem to affect the long-term 
clinical outcome. We believe that needle-track seeding from 
HCC does not modify clinical course, because tumor 
involvement in needle-tracks appears to be limited to 
subcutaneous tissues at puncture sites.
31 Accordingly, we 
believe that aggressive local ablative treatment, such as, 
en-bloc wide excision, can effectively remove needle-track 
seeding. Furthermore, the prognosis of HCC is usually not 
dependent on the severity of metastatic lesions, but rather on 
hepatic functional reserve and on the characteristics of 
intrahepatic lesions.
32
Based on the rationale that HCC infiltrates surrounding 
tissues and that several needle passes are conducted, we 
recommend that en-bloc wide excision of implanted nodules, 
including surrounding tissues, should be used to treat 
needle-track seeding from HCC rather than mass excision. 
However, Takahashi et al in a report of the recurrence of 
needle-track seeding after wide excision suggested that 
needle-tract seeding is not a local, limited disease.
33 
Nevertheless, their patient was treated by wide excision and 
radiotherapy and remained alive without evidence of 
recurrence, which reinforces the point that aggressive local 
treatment is well worth considering. 
The current study has some limitations that should be 
mentioned. First, the number of patients enrolled and the 
follow-up period were not enough to determine the effects 
of the surgical method used to treat needle-track seeding 
on clinical outcome. Second, one of the two patients 
who experienced the recurrence of needle-track seeding 
after surgical excision had combined hepatocellular- 
cholangiocarcinoma and long-term clinical outcome of this 
patient could not be evaluated because of loss of follow-up. 
Combined hepatocellular-cholangiocarcinoma is known to 
have a poorer prognosis than the ordinary HCC.
34 In the 
current study, the frequency of needle-track seeding in 
patients with combined hepatocellular-cholangiocarcinoma 
was 12.5%, which is much larger than that in patients with 
ordinary HCC. Nevertheless, we believe that en-bloc wide 
excision might be also useful for the treatment of needle- 
track seeding in this subgroup. Further studies in this 
subgroup will be needed to clarify this issue.
Recently, the long term survivals of HCC patients are 
increasing due, in no small part, to the introductions of 
curative local ablation and liver transplantation. The current 
study shows that needle-track seeding can be curatively 
treated by en-bloc excision without recurrence, and that 
therefore, it should not be considered to be similar to 
systemic metastasis. Therefore our findings indicate that 
needle-track seeding, if it is treated by en-bloc wide excision, 
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transplantation.
Taken together, needle-track seeding after PEI or FNAB 
by HCC is a rare but important complication, and it can also 
occur after PTBD for biliary obstruction by HCC. However, 
the result of follow-up indicates that the prognosis of 
needle-track seeding, when it is treated by en-bloc wide 
excision, is favorable. Our results suggest that implanted 
nodules should be treated by en-bloc wide excision in cases 
with needle-track seeding from HCC after an US-guided 
procedure, especially in patients awaiting liver trans-
plantation.
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